에서 실시간으로 운영 중이에요! 자세히 알아보기
DVAX 아이콘

Dynavax Technologies
DVAX

상장 폐지됨

DVAX은(는) 2026년 2월 9일에 상장 폐지됐어요.

순위로 돌아가기
 

소개: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

직원 수: 405

건강관리 의약품 제조업체 - 전문의약품 및 제네릭

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 0%
중립 0%
부정적 0%
중립
The Motley Fool
8개월 전
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
114,000 shares were exercised and sold on Jan. 15, 2026, for a transaction value of approximately ~$1.8 million, at a weighted average price of around $15.64 per share. The entire trade was executed via direct holdings through an option exercise and immediate sale, with no indirect entities involved.
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
중립
PRNewsWire
9개월 전
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Dynavax Technologies Corporation (NASDAQ: DVAX) related to its sale to Sanofi.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)
중립
PRNewsWire
9개월 전
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
중립
Business Wire
9개월 전
CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Please replace the release issued December 29, 2025 with the following corrected version due to multiple revisions. The updated release reads: DYNAVAX INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF DYNAVAX TECHNOLOGIES CORPORATION - DVAX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale o.
CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
중립
Business Wire
9개월 전
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY). Under the terms of the proposed transaction, shareholders of Cidara will receive $221.50 in cash for each share of Cidara that they own. KSF is seeking to determine whether this consideration and the process that led to it.
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
긍정적
The Motley Fool
9개월 전
Why Dynavax Stock Soared Today
Sanofi is launching an all-cash tender offer for Dynavax's shares. The French pharma giant's bid comes at a sizable premium to Dynavax's recent closing price.
Why Dynavax Stock Soared Today
긍정적
Schaeffers Research
9개월 전
Dynavax Technologies Stock Soars on Buyout Buzz
Biotech stock Dynavax Technologies Corp (NASDAQ:DVAX) is soaring today, last seen up 38.7% at $15.43, after reports that Sanofi (SNY) plans to acquire the company in an all-cash deal worth roughly $2.2 billion.
Dynavax Technologies Stock Soars on Buyout Buzz
중립
PRNewsWire
9개월 전
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
MILWAUKEE , Dec. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Dynavax (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
긍정적
Investopedia
9개월 전
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying
Shares of Dynavax Technologies (DVAX) skyrocketed after French drugmaker Sanofi (SNY) said it would buy the biopharmaceutical firm for $2.2 billion to expand its Hepatitis B offerings and enter the shingles vaccine market.
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying
긍정적
Proactive Investors
9개월 전
Sanofi to acquire Dynavax in $2.2B Deal to boost adult vaccines
French pharmaceutical giant Sanofi SA said on Wednesday it has agreed to acquire US-based vaccines company Dynavax Technologies Corp in a $2.2 billion deal, strengthening its presence in the adult immunization market. Under the agreement, Sanofi will launch a cash tender offer of $15.50 per Dynavax share, representing a 39% premium to the company's pre-deal stock price.
Sanofi to acquire Dynavax in $2.2B Deal to boost adult vaccines
뉴스 순위 보기
Lightweight Charts™를 사용해 가격 차트를 구현했어요.